Compare DoorDash Inc (DASH) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs Summit Therapeutics Inc — how do they compare? DoorDash Inc trades at $212.2 (market cap $91.86B), while Summit Therapeutics Inc trades at $15.5 (market cap $12.06B). The key difference: DoorDash Inc is far larger — about 7.6× Summit Therapeutics Inc's market cap, and DoorDash Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| DASH | SMMT | |
|---|---|---|
Market Cap | $91.86B | $12.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $281.74 | $26.98 |
52-Week Low | $146.60 | $12.55 |
Enterprise Value | $89.82B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $209.86, down 2.96% today, amid mixed earnings results but strong revenue growth. The stock shows a bullish technical trend above key support levels, with a 75.68% analyst buy rating. Recent Q2 2026 revenue beat expectations, though EPS missed due to higher R&D costs, while the company projects robust Q3 growth and continues investing in AI and autonomous delivery.
Outlook remains positive driven by expanding market share and profitability, but risks include intense competition and cost pressures. The consensus price target of $247.41 suggests ~18% upside, supported by solid cash flow and strategic acquisitions, though valuation multiples are elevated.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
